cancer-2018-posters-abstracts

Page 60

Notes:

allied

academies

Journal of Medical Oncology and Therapeutics | Volume: 3

July 23-25, 2018 | Moscow, Russia

World Cancer Congress

Anti-Cancer immune response as instrument for early diagnostic and treatment of malignant tumors

Alexander Poletaev

Federal Clinical & Research Ctr. of Intensive Care and Rehabilitation, Russia

he low efficiency of targeted therapy in oncology, which

became a surprise for molecular pharmacologists, is not

result of miscalculations in the choice of molecular targets for

monoclonal antibodies, but rather in the wrong initial paradigm.

Attempts to defeat cancer by targeted antibodies can be likened

to fruitless attempts to destroy a holographic image with the

break of the hologram fragments (main feature of the hologram

is the fundamental indivisibility of the image). The systemic

phenomenon of malignancy scarcely be sensitive to targeted

“breaks”. Hardly we will be able to solve the problem, if do not

realize the words Dr. Zalmanoff: “Attempts to find an antidote

to cancer are fruitless, because the key is not a cancer cell, but

a person affected by cancer.” Cancer is a disease of the whole

organism, not the genomes of individual cells. Accordingly,

the most effective approaches rather be restoration the

organismal supervision and control over the tissues growth and

differentiation, but not attempts of destroying themalignancy by

external agents (chemical or physical). Key may be related to the

abilityoftheimmunesystemoftumor-bearingpatient“tosee”the

malignant cells. This is proved by the presence of autoantibodies

to tumor-associated antigens in such patients. Why the immune

system usually does not destroy malignant cells? How to

activate internal anti-tumoral mechanisms? Can antibodies

to tumor-associated antigens be used for early serological

diagnosis of malignant tumors? These issues will be discussed.